在早期三阴性乳腺癌中以蒽环类-紫杉类为基础的新辅助治疗中加入度伐利尤单抗的随机II期研究:GeparNuevo研究的临床结果与生物标志物分析
GeparNuevo是一项随机II期双盲安慰剂对照研究,评估在早期三阴性乳腺癌标准新辅助化疗(白蛋白结合型紫杉醇序贯EC)基础上加入度伐利尤单抗的疗效。174例患者随机分组,其中117例参与窗口期(化疗前单用度伐利尤单抗/安慰剂2周)。总体pCR率度伐利尤单抗组53.4% vs 安慰剂组44.2%(未校正P=0.287),OR=1.45(95%CI 0.80-2.63);窗口期队列pCR率61.0% vs 41.4%(OR=2.22,95%CI 1.06-4.64,P=0.035;交互P=0.048)。
要点
- 总体人群pCR率度伐利尤单抗组53.4% vs 安慰剂组44.2%,未达统计学显著(未校正P=0.287)。
- 窗口期队列pCR率度伐利尤单抗组61.0% vs 安慰剂组41.4%(OR=2.22,95%CI 1.06-4.64,P=0.035)。
- 最常见的免疫相关不良事件为甲状腺功能障碍,任何级别占47%。
核心结论
- 作者认为,在蒽环类/紫杉类为基础的新辅助化疗中加入度伐利尤单抗可提高pCR率,尤其在化疗开始前单用度伐利尤单抗的患者中更为明显。
研究设计与样本
- GeparNuevo为随机II期双盲安慰剂对照研究,将三阴性乳腺癌患者随机分配至度伐利尤单抗组或安慰剂组,每4周给药一次,联合白蛋白结合型紫杉醇序贯标准EC方案。
- 窗口期在开始白蛋白结合型紫杉醇前2周单用度伐利尤单抗/安慰剂;随机化按间质肿瘤浸润淋巴细胞(sTILs)分层。
- 纳入标准为原发cT1b-cT4a-d疾病、中心确认的三阴性乳腺癌且有sTILs;主要终点为病理完全缓解(pCR,ypT0 ypN0)。
- 共174例患者随机分组,其中117例参与窗口期;中位年龄49.5岁(范围23-76),47例(27%)小于40岁,113例(65%)为≥IIA期,25例(14%)sTILs高,158例中138例(87%)PD-L1阳性。
主要发现
- 度伐利尤单抗组pCR率为53.4%(95%CI 42.5%-61.4%),安慰剂组为44.2%(95%CI 33.5%-55.3%),未校正连续性校正χ2检验P=0.287,对应OR=1.45(95%CI 0.80-2.63,未校正Wald检验P=0.224)。
- 窗口期队列中,度伐利尤单抗组pCR率61.0% vs 安慰剂组41.4%(OR=2.22,95%CI 1.06-4.64,P=0.035;交互作用P=0.048)。
- 两组中sTILs较高者pCR率均显著升高(P<0.01)。
- PD-L1阳性肿瘤中pCR率有升高趋势,度伐利尤单抗组PD-L1肿瘤细胞阳性者P=0.045,安慰剂组PD-L1免疫细胞阳性者P=0.040。
- 最常见的免疫相关不良事件为甲状腺功能障碍,任何级别占47%。
关键数值与推荐
- 主要终点pCR(ypT0 ypN0):度伐利尤单抗组53.4%(95%CI 42.5%-61.4%)vs 安慰剂组44.2%(95%CI 33.5%-55.3%),未校正连续性校正χ2检验P=0.287。
- 总体OR=1.45(95%CI 0.80-2.63,未校正Wald检验P=0.224)。
- 窗口期队列pCR率:度伐利尤单抗组61.0% vs 安慰剂组41.4%,OR=2.22(95%CI 1.06-4.64,P=0.035),交互作用P=0.048。
- sTILs较高者两组pCR率均显著升高(P<0.01)。
- PD-L1阳性肿瘤中pCR率有升高趋势:度伐利尤单抗组PD-L1肿瘤细胞阳性P=0.045;安慰剂组PD-L1免疫细胞阳性P=0.040。
临床怎么用
- 作者认为,在蒽环类/紫杉类为基础的新辅助化疗中加入度伐利尤单抗可提高pCR率,尤其在化疗开始前单用度伐利尤单抗的患者中更为明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC). Therefore, we evaluated the addition of durvalumab to standard neoadjuvant chemotherapy (NACT) in primary TNBC. PATIENTS AND METHODS: GeparNuevo is a randomised phase II double-blind placebo-controlled study randomising patients with TNBC to durvalumab or placebo given every 4 weeks in addition to nab-paclitaxel followed by standard EC. In the window-phase durvalumab/placebo alone was given 2 weeks before start of nab-paclitaxel. Randomisation was stratified by stromal tumour-infiltrating lymphocyte (sTILs). Patients with primary cT1b-cT4a-d disease, centrally confirmed TNBC and sTILs were included. Primary objective was pathological complete response (pCR) (ypT0 ypN0). RESULTS: A total of 174 patients were randomised, 117 participated in the window-phase. Median age was 49.5 years (range 23-76); 47 patients (27%) were younger than 40 years; 113 (65%) had stage ≥IIA disease, 25 (14%) high sTILs, 138 of 158 (87%) were PD-L1-positive. pCR rate with durvalumab was 53.4% (95% CI 42.5% to 61.4%) versus placebo 44.2% (95% CI 33.5% to 55.3%; unadjusted continuity corrected χ2P = 0.287), corresponding to OR = 1.45 (95% CI 0.80-2.63, unadjusted Wald P = 0.224). Durvalumab effect was seen only in the window cohort (pCR 61.0% versus 41.4%, OR = 2.22, 95% CI 1.06-4.64, P = 0.035; interaction P = 0.048). In both arms, significantly increased pCR (P < 0.01) were observed with higher sTILs. There was a trend for increased pCR rates in PD-L1-positive tumours, which was significant for PD-L1-tumour cell in durvalumab (P = 0.045) and for PD-L1-immune cell in placebo arm (P = 0.040). The most common immune-related adverse events were thyroid dysfunction any grade in 47%. CONCLUSIONS: Our results suggest that the addition of durvalumab to anthracycline-/taxane-based NACT increases pCR rate particularly in patients treated with durvalumab alone before start of chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT02685059.
引用
- Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019. PMID: 31095287. doi:10.1093/annonc/mdz158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。